S-EPMC10508135 - A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations. - OmicsDI

Unknown

Dataset Information

A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations.

ABSTRACT:

SUBMITTER: Wang P

PROVIDER: S-EPMC10508135 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature